Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.29, $0.01 better than the analyst estimate of $0.28. Revenue for the quarter came in at $80.4 million versus the consensus estimate of $80 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.